Elicio Therapeutics, a longstanding client of Occam Global's, has strengthened its leadership team with the appointment of Annette Matthies, PhD, as Chief Business Officer. Elicio Therapeutics is advancing its ground-breaking Amphiphile technology across immunotherapy and vaccine platforms to develop therapies for cancer and infectious disease.
Annette, trained as an immunologist and broadly experienced across therapeutic areas including oncology, will spearhead Elicio's business and corporate development initiatives with a particularly strong focus on partnership opportunities in 2021. Most recently, Annette served as VP of Corporate Development at eFFECTOR Therapeutics. Prior to that, she was an integral member of the corporate development teams of Receptos, acquired by Celgene for $7.2B, and Facet Biotech, acquired by Abbott Laboratories for $450M.
Previously, Occam placed Christopher Haqq MD/PhD as EVP, Head of R&D and Chief Medical Officer. More recently, Occam recruited Daphne Karydas to join Elicio's Board of Directors.
